Holen Sie sich die Stockscreener-App
1.79
10.50%
-0.21
Schlusskurs vom Vortag:
$2.00
Offen:
$1.98
24-Stunden-Volumen:
453.87K
Relative Volume:
0.74
Marktkapitalisierung:
$15.44M
Einnahmen:
$2.47M
Nettoeinkommen (Verlust:
$-24.73M
KGV:
-0.4249
EPS:
-4.213
Netto-Cashflow:
$-20.36M
1W Leistung:
-32.96%
1M Leistung:
-23.18%
6M Leistung:
-70.14%
1J Leistung:
-84.49%
1-Tages-Spanne:
$1.75
$2.03
1-Wochen-Bereich:
$1.75
$2.90
52-Wochen-Spanne:
$1.75
$18.80
VolitionRX Ltd Stock (VNRX) Company Profile
Firmenname
VolitionRX Ltd
Sektor
Branche
Telefon
646 650 1351
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
1.79 | 17.25M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Eingeleitet | Maxim Group | Buy |
| 2018-05-14 | Bestätigt | The Benchmark Company | Buy |
| 2016-09-07 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-02-01 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
VolitionRx (VNRX) files shelf prospectus for stock, detachable warrants - Stock Titan
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com
New Ebola triage blood test: VolitionRx seeks partners for outbreak zones - Stock Titan
VolitionRx (NYSE: VNRX) seeks approval to cut authorized shares and add 2026 stock plan - Stock Titan
Benchmark reiterates Hold on VolitionRX stock amid milestones By Investing.com - Investing.com South Africa
Benchmark reiterates Hold on VolitionRX stock amid milestones - Investing.com
VolitionRx Ltd stock (US92852X1037): shares trade quietly after May earnings update - AD HOC NEWS
VolitionRX (VNRX) Insider Trading Activity 2026 - MarketBeat
VolitionRx : Short Corporate Deck, May 2026 - marketscreener.com
VNRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VolitionRx reports 300% Q1 revenue growth, nears vet milestone By Investing.com - Investing.com South Africa
VolitionRx reports 300% Q1 revenue growth, nears vet milestone - Investing.com
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets - Moomoo
VolitionRx targets $27B market with finger-prick sepsis and early cancer tests - Stock Titan
VolitionRX Limited (VNRX) Slides 6% as Stock Tests Key Support LevelsParabolic SAR - newsline.com
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Yahoo Finance UK
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and NYSE Listing - Minichart
VolitionRx receives waiver on market capitalization covenant from Lind Global - Investing.com
VolitionRx Obtains Covenant Waiver on $9.9 Million Convertible Notes From Lind, Avoiding Acceleration - TradingView
Covenant breach leads VolitionRx (NYSE: VNRX) to secure Lind waiver and note changes - Stock Titan
VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk - TipRanks
VolitionRX Earnings Call Balances Breakthroughs and Risks - TipRanks
VolitionRx Limited (AMEX:VNRX) Q1 2026 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth - GuruFocus
VolitionRx director Mickie Henshall to step down, board size to be reduced - Investing.com Australia
VolitionRx director Mickie Henshall to step down, board size to be reduced By Investing.com - Investing.com South Africa
Mickie Henshall to Leave Volition Board; Company to Reduce Board Size - TradingView
VolitionRx (VNRX) director exits at 2026 meeting as board shrinks to seven - Stock Titan
Lagoda holds 17.07M VolitionRX shares after amendment (VNRX) - Stock Titan
Earnings call transcript: VolitionRx Q1 2026 sees revenue surge, EPS miss - Investing.com
Full Transcript: VolitionRX Q1 2026 Earnings Call - Benzinga
Q1 2026 VolitionRX Ltd Earnings Call Transcript - GuruFocus
Is VolitionRX (VNRX) a Value Trap After Q1 2026? EPS Not Disclos - GuruFocus
VolitionRX: Q1 Earnings Snapshot - marketscreener.com
VolitionRx Ltd stock (US92852X1037): Q1 2026 update and epigenetics business profile - AD HOC NEWS
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026 - Stock Titan
VolitionRx (NYSE: VNRX) lifts Q1 2026 revenue and secures new funding - Stock Titan
Cat cancer blood test may unlock $5M payout for VolitionRx - Stock Titan
VolitionRX Q1 2026 Earnings Call Transcript - MarketBeat
VolitionRx (VNRX) seeks approval to cut authorized shares and adopt 2026 equity plan - Stock Titan
VNRX Technical Analysis | Trend, Signals & Chart Patterns | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
TradingKey - TradingKey
Earnings Preview: VolitionRX to Report Financial Results Pre-market on May 15 - Moomoo
Press Release: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update - Moomoo
What to expect from VolitionRx’s May 15 Q1 2026 earnings call - Stock Titan
MSN Money - MSN
VolitionRx (VNRX) Advances Feline Cancer Detection Research with New Submission - GuruFocus
BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study - StreetInsider
A blood test for cat lymphoma showed 86% detection at 97% specificity - Stock Titan
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats - Financial Times
Finanzdaten der VolitionRX Ltd-Aktie (VNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):